As filed with the Securities and Exchange Commission on March 31, 2026 Registration No. 333-294716 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VivoSim Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 27-1488943 (State or other jurisdiction of incorporation or organization) (Primary Standard Classification Code Number) (I.R.S. Employer Identification Number) 11555 Sor ...

As filed with the Securities and Exchange Commission on March 27, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VivoSim Labs, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 27-1488943 (Primary Standard Classification Code Number) (I.R.S. Employer Identification Number) 11555 Sorrento Valley Road, Suite 100 San Diego, CA 9212 ...

Financial Data and Key Metrics Changes - Agilent reported Q1 2026 revenue of $1.8 billion, growing 4.4% on a core basis, with a reported growth of 7% [5][24] - Operating margins were 24.6%, in line with expectations, and down 50 basis points year-over-year due to increased tariff expenses [7][26] - Q1 EPS was $1.36, reflecting a 4% growth, and adjusted for the weather impact, it would have exceeded the midpoint of guidance [7][26] Business Segment Data and Key Metrics Changes - Agilent CrossLab Group (ACG) grew 6%, driven by strong consumables growth and solid performance in services [24] - Applied Markets Group (AMG) grew 4%, led by double-digit performance in spectroscopy [24] - Life Sciences and Diagnostics Group (LDG) grew 3%, slightly below expectations due to weather impact and softness in academia and government [25][60] Market Data and Key Metrics Changes - Pharma growth was 7%, with double-digit growth in biotech, supported by increased funding and M&A activity [17] - Advanced materials market grew 20%, driven by semiconductor reshoring and strong demand for atomic spectroscopy tools [18][80] - Environmental and forensics market was flat, while the food business declined 4%, outperforming expectations [18][19] Company Strategy and Development Direction - Agilent is focused on enhancing customer intimacy through differentiated service offerings and leveraging the Ignite operating system for operational excellence [8][15] - The company aims to capture opportunities from improving end markets, innovative products, and a multi-pronged replacement cycle [22] - Agilent is maintaining its expected core growth range of 4%-6% for the full year, with a focus on disciplined capital deployment and strategic M&A [22][31] Management's Comments on Operating Environment and Future Outlook - Management noted a solid start to the year with underlying momentum in key markets, despite challenges from weather and macroeconomic conditions [5][16] - The company expects continued growth in pharma, diagnostics, and advanced materials, with a billion-dollar addressable market opportunity from reshoring [21][22] - Management remains optimistic about the second quarter, expecting core growth of approximately 4%-5.5% [22][32] Other Important Information - Operating cash flow for Q1 was $268 million, with $93 million invested in CapEx and $152 million in share repurchases [27] - The company ended the quarter with a net leverage ratio of 0.8 turns, maintaining a strong balance sheet [27] - Agilent's Ignite operating system has delivered clear financial results, including pricing realization and procurement savings [15][30] Q&A Session Summary Question: Impact of the snowstorm and expectations for catch-up - Management confirmed a $10 million revenue impact from the snowstorm, with most of it already recovered, and a modest impact on margins [37][38] Question: Margin improvement cadence - The second quarter is expected to show a 50 basis point improvement driven by pricing, volume, and Ignite savings, offset by performance-based pay and tariffs [39][40] Question: Visibility on back half growth - Management highlighted strong underlying momentum in key markets, particularly in pharma and advanced materials, as drivers for growth in the second half [42][44] Question: Tariff assumptions post-Supreme Court ruling - Management stated that current guidance remains unchanged despite the dynamic tariff situation, with no significant changes expected [48][49] Question: Capital equipment demand trends - Management noted steady demand in capital equipment, with no signs of deterioration, and a reasonable budget flush observed at the end of December [52][54] Question: M&A environment and appetite - Management emphasized a disciplined approach to M&A, focusing on strategic fits and financial attractiveness, without needing transformative deals [55][56] Question: LDG segment performance - Management acknowledged challenges in the LDG segment due to weather and academic market softness, but expressed optimism for future improvements [60][62] Question: Specialty CDMO growth visibility - Management confirmed low double-digit growth in the specialty CDMO segment, with expectations for mid-teens growth for the full year based on production schedules [65][66]